{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:00:46Z","timestamp":1790694046323,"version":"4.1.0"},"reference-count":188,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T00:00:00Z","timestamp":1610496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RIER network RD16\/0012 RETICS program"],"award-info":[{"award-number":["RIER network RD16\/0012 RETICS program"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":[".."],"award-info":[{"award-number":[".."]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>The complement system (CS) includes more than 50 proteins and its main function is to recognize and protect against foreign or damaged molecular components. Other homeostatic functions of CS are the elimination of apoptotic debris, neurological development, and the control of adaptive immune responses. Pathological activation plays prominent roles in the pathogenesis of most autoimmune diseases such as systemic lupus erythematosus, antiphospholipid syndrome, rheumatoid arthritis, dermatomyositis, and ANCA-associated vasculitis. In this review, we will review the main rheumatologic autoimmune processes in which complement plays a pathogenic role and its potential relevance as a therapeutic target.<\/jats:p>","DOI":"10.3390\/cells10010148","type":"journal-article","created":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T11:52:32Z","timestamp":1610538752000},"page":"148","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Complement as a Therapeutic Target in Systemic Autoimmune Diseases"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7264-2577","authenticated-orcid":false,"given":"Mar\u00eda","family":"Galindo-Izquierdo","sequence":"first","affiliation":[{"name":"Servicio de Reumatolog\u00eda, Instituto de Investigaci\u00f3n 12 de Octubre, Universidad Complutense de Madrid, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Pablos Alvarez","sequence":"additional","affiliation":[{"name":"Servicio de Reumatolog\u00eda, Instituto de Investigaci\u00f3n 12 de Octubre, Universidad Complutense de Madrid, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,1,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.15252\/embj.201591881","article-title":"Complement Activation, Regulation, and Molecular Basis for Complement-Related Diseases","volume":"34","author":"Bajic","year":"2015","journal-title":"EMBO J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nrneph.2016.70","article-title":"Complement in Disease: A Defence System Turning Offensive","volume":"12","author":"Ricklin","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/978-1-4419-0901-5_8","article-title":"Target Pattern Recognition by Complement Proteins of the Classical and Alternative Pathways","volume":"653","author":"Kang","year":"2009","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1042\/bj1750383","article-title":"Activation of the First Component of Human Complement (C1) by Antibody-Antigen Aggregates","volume":"175","author":"Dodds","year":"1978","journal-title":"Biochem. J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1042\/bst0301001","article-title":"Structural Biology of C1","volume":"30","author":"Arlaud","year":"2002","journal-title":"Biochem. Soc. Trans."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.molimm.2013.05.220","article-title":"Toward a Structure-Based Comprehension of the Lectin Pathway of Complement","volume":"56","author":"Kjaer","year":"2013","journal-title":"Mol. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.3389\/fimmu.2018.01851","article-title":"Be on Target: Strategies of Targeting Alternative and Lectin Pathway Components in Complement-Mediated Diseases","volume":"9","author":"Kocsis","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/cei.12909","article-title":"Lectin Complement Pathway Proteins in Healthy Individuals","volume":"188","author":"Troldborg","year":"2017","journal-title":"Clin. Exp. Immunol."},{"key":"ref_9","first-page":"1305","article-title":"The Central Role of the Alternative Complement Pathway in Human Disease","volume":"176","author":"Thurman","year":"2006","journal-title":"J. Immunol. Baltim. Md. 1950"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0065-2776(08)04004-2","article-title":"The Amplification Loop of the Complement Pathways","volume":"104","author":"Lachmann","year":"2009","journal-title":"Adv. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1016\/j.molimm.2009.04.027","article-title":"The Role of the Anaphylatoxins in Health and Disease","volume":"46","author":"Klos","year":"2009","journal-title":"Mol. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2353\/ajpath.2007.070166","article-title":"The Role of Complement in Inflammatory Diseases from behind the Scenes into the Spotlight","volume":"171","author":"Markiewski","year":"2007","journal-title":"Am. J. Pathol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nri2620","article-title":"Complement Regulators and Inhibitory Proteins","volume":"9","author":"Zipfel","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/j.1440-1797.2010.01373.x","article-title":"Review: Complement and Its Regulatory Proteins in Kidney Diseases","volume":"15","author":"Lesher","year":"2010","journal-title":"Nephrol. Carlton Vic."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/ni.1923","article-title":"Complement: A Key System for Immune Surveillance and Homeostasis","volume":"11","author":"Ricklin","year":"2010","journal-title":"Nat. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"565","DOI":"10.3389\/fimmu.2014.00565","article-title":"Deciphering the Fine Details of C1 Assembly and Activation Mechanisms: \u201cMission Impossible\u201d?","volume":"5","author":"Gaboriaud","year":"2014","journal-title":"Front. Immunol."},{"key":"ref_17","first-page":"5083","article-title":"The Novel Complement Inhibitor Human CUB and Sushi Multiple Domains 1 (CSMD1) Protein Promotes Factor I-Mediated Degradation of C4b and C3b and Inhibits the Membrane Attack Complex Assembly","volume":"27","author":"Kalchishkova","year":"2013","journal-title":"FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"10587","DOI":"10.1038\/ncomms10587","article-title":"Structural Basis of Complement Membrane Attack Complex Formation","volume":"7","author":"Serna","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.molimm.2017.05.024","article-title":"Demyelination, Strokes, and Eculizumab: Lessons from the Congenital CD59 Gene Mutations","volume":"89","author":"Tabib","year":"2017","journal-title":"Mol. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.molimm.2013.05.223","article-title":"Novel Roles for Complement Receptors in T Cell Regulation and Beyond","volume":"56","author":"Kemper","year":"2013","journal-title":"Mol. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1146\/annurev-immunol-032713-120154","article-title":"Complement and Its Receptors: New Insights into Human Disease","volume":"32","author":"Holers","year":"2014","journal-title":"Annu. Rev. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3389\/fimmu.2016.00036","article-title":"Early Components of the Complement Classical Activation Pathway in Human Systemic Autoimmune Diseases","volume":"7","author":"Lintner","year":"2016","journal-title":"Front. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/ng0598-56","article-title":"Homozygous C1q Deficiency Causes Glomerulonephritis Associated with Multiple Apoptotic Bodies","volume":"19","author":"Botto","year":"1998","journal-title":"Nat. Genet."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1126\/science.aao4555","article-title":"C1q Restrains Autoimmunity and Viral Infection by Regulating CD8+ T Cell Metabolism","volume":"360","author":"Ling","year":"2018","journal-title":"Science"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1093\/rheumatology\/kep387","article-title":"SLE with C1q Deficiency Treated with Fresh Frozen Plasma: A 10-Year Experience","volume":"49","author":"Mehta","year":"2010","journal-title":"Rheumatol. Oxf. Engl."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3389\/fimmu.2016.00055","article-title":"Systemic Lupus Erythematosus and Deficiencies of Early Components of the Complement Classical Pathway","volume":"7","author":"Macedo","year":"2016","journal-title":"Front. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.ajhg.2011.05.011","article-title":"Disease-Causing Mutations in Genes of the Complement System","volume":"88","author":"Degn","year":"2011","journal-title":"Am. J. Hum. Genet."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s13238-012-2924-6","article-title":"Complement Genetics, Deficiencies, and Disease Associations","volume":"3","author":"Mayilyan","year":"2012","journal-title":"Protein Cell"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1080\/08820139.2016.1237525","article-title":"Mannose-Binding Lectin Deficiency in Brazilian Patients with Spondyloarthritis","volume":"46","author":"Skare","year":"2017","journal-title":"Immunol. Investig."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s11033-012-2135-5","article-title":"Association of RANTES and MBL Gene Polymorphisms with Systemic Lupus Erythematosus: A Meta-Analysis","volume":"40","author":"Xu","year":"2013","journal-title":"Mol. Biol. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.3899\/jrheum.171033","article-title":"The Lectin Pathway of Complement Activation in Patients with Systemic Lupus Erythematosus","volume":"45","author":"Troldborg","year":"2018","journal-title":"J. Rheumatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1365-3083.2006.01729.x","article-title":"Clinical Aspects and Molecular Basis of Primary Deficiencies of Complement Component C3 and Its Regulatory Proteins Factor I and Factor H","volume":"63","author":"Isaac","year":"2006","journal-title":"Scand. J. Immunol."},{"key":"ref_33","first-page":"698","article-title":"The Response of Serum Gamma Globulin Level and Complement Titer to Adrenocorticotropic Hormone Therapy in Lupus Erythematosus Disseminatus","volume":"37","author":"Vaughan","year":"1951","journal-title":"J. Lab. Clin. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJM196803072781004","article-title":"Immunologic Factors and Clinical Activity in Systemic Lupus Erythematosus","volume":"278","author":"Schur","year":"1968","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1002\/art.1780280810","article-title":"The Value of Complement and Immune Complex Determinations in Monitoring Disease Activity in Patients with Systemic Lupus Erythematosus","volume":"28","author":"Valentijn","year":"1985","journal-title":"Arthritis Rheum."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/10408368609110272","article-title":"Complement in the Pathophysiology and Diagnosis of Human Diseases","volume":"24","author":"Dalmasso","year":"1986","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/art.1780390716","article-title":"Sensitivity and Specificity of Plasma and Urine Complement Split Products as Indicators of Lupus Disease Activity","volume":"39","author":"Manzi","year":"1996","journal-title":"Arthritis Rheum."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1177\/0961203316645205","article-title":"Anti-C1q in Systemic Lupus Erythematosus","volume":"25","author":"Stojan","year":"2016","journal-title":"Lupus"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3389\/fimmu.2013.00117","article-title":"Anti-C1q Autoantibodies, Novel Tests, and Clinical Consequences","volume":"4","author":"Mahler","year":"2013","journal-title":"Front. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1046\/j.1365-2249.2003.02274.x","article-title":"Autoantibodies against Mannose-Binding Lectin in Systemic Lupus Erythematosus","volume":"134","author":"Seelen","year":"2003","journal-title":"Clin. Exp. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Plawecki, M., Lheritier, E., Clavarino, G., Jourde-Chiche, N., Ouili, S., Paul, S., Gout, E., Sarrot-Reynauld, F., Bardin, N., and Bo\u00eblle, P.-Y. (2016). Association between the Presence of Autoantibodies Targeting Ficolin-3 and Active Nephritis in Patients with Systemic Lupus Erythematosus. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0160879"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1177\/0961203312451202","article-title":"Diagnostic Value of Serum Anti-C1q Antibodies in Patients with Lupus Nephritis: A Meta-Analysis","volume":"21","author":"Yin","year":"2012","journal-title":"Lupus"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.34381","article-title":"Increased IgG on Cell-Derived Plasma Microparticles in Systemic Lupus Erythematosus Is Associated with Autoantibodies and Complement Activation","volume":"64","author":"Nielsen","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0022-1759(84)90031-0","article-title":"A New Enzyme-Linked Immunosorbent Assay (ELISA) for Measuring Immunoconglutinins Directed against the Third Component of Human Complement. Findings in Systemic Lupus Erythematosus","volume":"73","author":"Durand","year":"1984","journal-title":"J. Immunol. Methods"},{"key":"ref_45","first-page":"2101","article-title":"IgG Autoantibodies against Deposited C3 Inhibit Macrophage-Mediated Apoptotic Cell Engulfment in Systemic Autoimmunity","volume":"187","author":"Kenyon","year":"2011","journal-title":"J. Immunol. Baltim. Md. 1950"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2215\/CJN.03990415","article-title":"Relationship of Circulating Anti-C3b and Anti-C1q IgG to Lupus Nephritis and Its Flare","volume":"11","author":"Birmingham","year":"2016","journal-title":"Clin. J. Am. Soc. Nephrol. CJASN"},{"key":"ref_47","first-page":"i71","article-title":"Biomarkers of Lupus Nephritis Histology and Flare: Deciphering the Relevant amidst the Noise","volume":"32","author":"Birmingham","year":"2017","journal-title":"Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. Eur. Ren. Assoc."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"25343","DOI":"10.1074\/jbc.M115.647008","article-title":"Functional Characterization of Autoantibodies against Complement Component C3 in Patients with Lupus Nephritis","volume":"290","author":"Vasilev","year":"2015","journal-title":"J. Biol. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1177\/0961203309357059","article-title":"C1-Inhibitor Autoantibodies in SLE","volume":"19","author":"Farkas","year":"2010","journal-title":"Lupus"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.autrev.2008.06.002","article-title":"Immune Complex Clearance by Complement Receptor Type 1 in SLE","volume":"8","author":"Kavai","year":"2008","journal-title":"Autoimmun. Rev."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0165-2478(03)00066-X","article-title":"Deficiency of Red Cell Bound CD55 and CD59 in Patients with Systemic Lupus Erythematosus","volume":"88","author":"Rodriguez","year":"2003","journal-title":"Immunol. Lett."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.cellimm.2010.07.013","article-title":"Expression of CD55 and CD59 on Peripheral Blood Cells from Systemic Lupus Erythematosus (SLE) Patients","volume":"265","author":"Alegretti","year":"2010","journal-title":"Cell. Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1046\/j.1365-2249.1999.00917.x","article-title":"Elevated Serum Levels of Soluble Membrane Cofactor Protein (CD46, MCP) in Patients with Systemic Lupus Erythematosus (SLE)","volume":"116","author":"Kawano","year":"1999","journal-title":"Clin. Exp. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"8502","DOI":"10.18632\/oncotarget.23907","article-title":"Serum Complement Factor I Is Associated with Disease Activity of Systemic Lupus Erythematosus","volume":"9","author":"Tseng","year":"2018","journal-title":"Oncotarget"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.molimm.2014.07.003","article-title":"Ficolins and the Lectin Pathway of Complement in Patients with Systemic Lupus Erythematosus","volume":"63","author":"Hein","year":"2015","journal-title":"Mol. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/art.1780260509","article-title":"Neutrophil Aggregation Induced by Sera from Patients with Active Systemic Lupus Erythematosus","volume":"26","author":"Abramson","year":"1983","journal-title":"Arthritis Rheum."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Karpman, D., and Kahn, R. (2009). The Contact\/Kinin and Complement Systems in Vasculitis. APMIS. Suppl., 48\u201354.","DOI":"10.1111\/j.1600-0463.2009.02477.x"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.atherosclerosis.2012.08.029","article-title":"Complement System and Small HDL Particles Are Associated with Subclinical Atherosclerosis in SLE Patients","volume":"225","author":"Parra","year":"2012","journal-title":"Atherosclerosis"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1084\/jem.200116116","article-title":"Complement C3 Activation Is Required for Antiphospholipid Antibody-Induced Fetal Loss","volume":"195","author":"Holers","year":"2002","journal-title":"J. Exp. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1172\/JCI200318817","article-title":"Complement C5a Receptors and Neutrophils Mediate Fetal Injury in the Antiphospholipid Syndrome","volume":"112","author":"Girardi","year":"2003","journal-title":"J. Clin. Investig."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1182\/blood-2005-03-1319","article-title":"Thrombus Formation Induced by Antibodies to Beta2-Glycoprotein I Is Complement Dependent and Requires a Priming Factor","volume":"106","author":"Fischetti","year":"2005","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/AOG.0b013e3181fc3afa","article-title":"Early Elevations of the Complement Activation Fragment C3a and Adverse Pregnancy Outcomes","volume":"117","author":"Lynch","year":"2011","journal-title":"Obstet. Gynecol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.molimm.2004.07.043","article-title":"A Novel Inhibitor of the Alternative Complement Pathway Prevents Antiphospholipid Antibody-Induced Pregnancy Loss in Mice","volume":"42","author":"Thurman","year":"2005","journal-title":"Mol. Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1681\/ASN.V94590","article-title":"CD59 Protects Glomerular Endothelial Cells from Immune-Mediated Thrombotic Microangiopathy in Rats","volume":"9","author":"Nangaku","year":"1998","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/art.21157","article-title":"Requirement of Activation of Complement C3 and C5 for Antiphospholipid Antibody-Mediated Thrombophilia","volume":"52","author":"Pierangeli","year":"2005","journal-title":"Arthritis Rheum."},{"key":"ref_66","first-page":"455","article-title":"Antiphospholipid Antibodies and Complement Activation in Patients with Cerebral Ischemia","volume":"10","author":"Davis","year":"1992","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1160\/TH11-08-0554","article-title":"Complement Activation in Patients with Isolated Antiphospholipid Antibodies or Primary Antiphospholipid Syndrome","volume":"107","author":"Breen","year":"2012","journal-title":"Thromb. Haemost."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1182\/blood-2015-09-672139","article-title":"Complement Activation in Antiphospholipid Syndrome and Its Inhibition to Prevent Rethrombosis after Arterial Surgery","volume":"127","author":"Meroni","year":"2016","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1182\/blood-2011-02-339564","article-title":"\u0392\u2082-Glycoprotein I, the Major Target in Antiphospholipid Syndrome, Is a Special Human Complement Regulator","volume":"118","author":"Gropp","year":"2011","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3389\/fimmu.2019.00449","article-title":"Complement in the Pathophysiology of the Antiphospholipid Syndrome","volume":"10","author":"Chaturvedi","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jri.2007.02.007","article-title":"Antiphospholipid Antibodies and Pregnancy Loss: A Disorder of Inflammation","volume":"77","author":"Salmon","year":"2008","journal-title":"J. Reprod. Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1136\/ard.2008.090670","article-title":"Complement Activation in Patients with Primary Antiphospholipid Syndrome","volume":"68","author":"Oku","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/00005792-199307000-00003","article-title":"Clinical Expression of Systemic Lupus Erythematosus in Patients with C4A Deficiency","volume":"72","author":"Petri","year":"1993","journal-title":"Med. (Baltim.)"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000233266","article-title":"Complement Components, C1 Activation and Disease Activity in SLE","volume":"70","author":"Sturfelt","year":"1983","journal-title":"Int. Arch. Allergy Appl. Immunol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/rheumatology\/keh407","article-title":"Hypocomplementaemia as an Immunological Marker of Morbidity and Mortality in Patients with Primary Sjogren\u2019s Syndrome","volume":"44","author":"Akasbi","year":"2005","journal-title":"Rheumatol. Oxf. Engl."},{"key":"ref_76","first-page":"54","article-title":"Complement Biosynthesis in Human Synovial Tissue","volume":"78","author":"Moffat","year":"1989","journal-title":"Clin. Exp. Immunol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0161-5890(99)00113-3","article-title":"Complement Activation and Inhibition in Experimental Models of Arthritis","volume":"36","author":"Linton","year":"1999","journal-title":"Mol. Immunol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/art.10183","article-title":"Local Production of Complement Proteins in Rheumatoid Arthritis Synovium","volume":"46","author":"Neumann","year":"2002","journal-title":"Arthritis Rheum."},{"key":"ref_79","first-page":"521","article-title":"C1 Inactivator-C1s Complexes in Inflammatory Joint Disease","volume":"53","author":"Inman","year":"1983","journal-title":"Clin. Exp. Immunol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/art.1780281003","article-title":"Elevated C3 Anaphylatoxin Levels in Synovial Fluids from Patients with Rheumatoid Arthritis","volume":"28","author":"Moxley","year":"1985","journal-title":"Arthritis Rheum."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1002\/art.1780291108","article-title":"Complement Activation in Synovial Fluid and Tissue from Patients with Juvenile Rheumatoid Arthritis","volume":"29","author":"Mollnes","year":"1986","journal-title":"Arthritis Rheum."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/BF02206833","article-title":"An Analysis of the Levels of Complement Components in the Synovial Fluid in Rheumatic Diseases","volume":"6","author":"Swaak","year":"1987","journal-title":"Clin. Rheumatol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/art.1780341209","article-title":"Synovial Fluid Levels of Complement SC5b-9 and Fragment Bb Are Elevated in Patients with Rheumatoid Arthritis","volume":"34","author":"Brodeur","year":"1991","journal-title":"Arthritis Rheum."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/rheumatology\/33.3.299","article-title":"Complement Degradation Products in Rheumatoid Arthritis Synovial Fluid","volume":"33","author":"Shingu","year":"1994","journal-title":"Br. J. Rheumatol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1136\/ard.47.3.190","article-title":"Relation between Synovial Fluid C3 Degradation Products and Local Joint Inflammation in Rheumatoid Arthritis, Osteoarthritis, and Crystal Associated Arthropathy","volume":"47","author":"Doherty","year":"1988","journal-title":"Ann. Rheum. Dis."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/ard.49.10.747","article-title":"Measurement of the Chemotactic Complement Fragment C5a in Rheumatoid Synovial Fluids by Radioimmunoassay: Role of C5a in the Acute Inflammatory Phase","volume":"49","author":"Jose","year":"1990","journal-title":"Ann. Rheum. Dis."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1136\/ard.55.12.888","article-title":"Complement in Acute and Chronic Arthritides: Assessment of C3c, C9, and Protectin (CD59) in Synovial Membrane","volume":"55","author":"Konttinen","year":"1996","journal-title":"Ann. Rheum. Dis."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000233956","article-title":"C1 Activation, with C1q in Excess of Functional C1 in Synovial Fluid from Patients with Rheumatoid Arthritis","volume":"79","author":"Berglund","year":"1986","journal-title":"Int. Arch. Allergy Appl. Immunol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1080\/07853890701477546","article-title":"Rheumatoid Arthritis and the Complement System","volume":"39","author":"Okroj","year":"2007","journal-title":"Ann. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/art.21729","article-title":"Evaluation of Classical Complement Pathway Activation in Rheumatoid Arthritis: Measurement of C1q-C4 Complexes as Novel Activation Products","volume":"54","author":"Wouters","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"32301","DOI":"10.1074\/jbc.M504828200","article-title":"The Extracellular Matrix and Inflammation: Fibromodulin Activates the Classical Pathway of Complement by Directly Binding C1q","volume":"280","author":"Onnerfjord","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.molimm.2008.09.018","article-title":"Short Leucine-Rich Glycoproteins of the Extracellular Matrix Display Diverse Patterns of Complement Interaction and Activation","volume":"46","author":"Manderson","year":"2009","journal-title":"Mol. Immunol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1002\/art.27720","article-title":"Regulation of Complement by Cartilage Oligomeric Matrix Protein Allows for a Novel Molecular Diagnostic Principle in Rheumatoid Arthritis","volume":"62","author":"Happonen","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Melin F\u00fcrst, C., M\u00f6rgelin, M., Vadstrup, K., Heineg\u00e5rd, D., Aspberg, A., and Blom, A.M. (2013). The C-Type Lectin of the Aggrecan G3 Domain Activates Complement. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0061407"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1002\/art.10591","article-title":"Mechanisms of Effects of Complement Inhibition in Murine Collagen-Induced Arthritis","volume":"46","author":"Banda","year":"2002","journal-title":"Arthritis Rheum."},{"key":"ref_96","first-page":"454","article-title":"Complement Deficiency Ameliorates Collagen-Induced Arthritis in Mice","volume":"169","author":"Hietala","year":"2002","journal-title":"J. Immunol. Baltim. Md. 1950"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/eji.200424895","article-title":"Complement Activation by Both Classical and Alternative Pathways Is Critical for the Effector Phase of Arthritis","volume":"34","author":"Hietala","year":"2004","journal-title":"Eur. J. Immunol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.3389\/fimmu.2018.01057","article-title":"Complement in the Initiation and Evolution of Rheumatoid Arthritis","volume":"9","author":"Holers","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1074-7613(02)00275-3","article-title":"Arthritis Critically Dependent on Innate Immune System Players","volume":"16","author":"Ji","year":"2002","journal-title":"Immunity"},{"key":"ref_100","first-page":"1904","article-title":"Alternative Complement Pathway Activation Is Essential for Inflammation and Joint Destruction in the Passive Transfer Model of Collagen-Induced Arthritis","volume":"177","author":"Banda","year":"2006","journal-title":"J. Immunol. Baltim. Md. 1950"},{"key":"ref_101","first-page":"4101","article-title":"Pathogenic Complement Activation in Collagen Antibody-Induced Arthritis in Mice Requires Amplification by the Alternative Pathway","volume":"179","author":"Banda","year":"2007","journal-title":"J. Immunol. Baltim. Md. 1950"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.molimm.2017.01.015","article-title":"Potential Influences of Complement Factor H in Autoimmune Inflammatory and Thrombotic Disorders","volume":"84","author":"Ferluga","year":"2017","journal-title":"Mol. Immunol."},{"key":"ref_103","first-page":"5928","article-title":"Targeted Inhibition of the Complement Alternative Pathway with Complement Receptor 2 and Factor H Attenuates Collagen Antibody-Induced Arthritis in Mice","volume":"183","author":"Banda","year":"2009","journal-title":"J. Immunol. Baltim. Md. 1950"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"R185","DOI":"10.1186\/ar4016","article-title":"Factor H Autoantibodies and Deletion of Complement Factor H-Related Protein-1 in Rheumatic Diseases in Comparison to Atypical Hemolytic Uremic Syndrome","volume":"14","author":"Zipfel","year":"2012","journal-title":"Arthritis Res. Ther."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/1529-0131(199904)42:4<650::AID-ANR7>3.0.CO;2-S","article-title":"Expression of the Activation Antigen CD97 and Its Ligand CD55 in Rheumatoid Synovial Tissue","volume":"42","author":"Hamann","year":"1999","journal-title":"Arthritis Rheum."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/art.27347","article-title":"Deletion of Either CD55 or CD97 Ameliorates Arthritis in Mouse Models","volume":"62","author":"Hoek","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S0092-8674(00)81989-3","article-title":"Organ-Specific Disease Provoked by Systemic Autoimmunity","volume":"87","author":"Kouskoff","year":"1996","journal-title":"Cell"},{"key":"ref_108","first-page":"450","article-title":"The Class II MHC I-Ag7 Molecules from Non-Obese Diabetic Mice Are Poor Peptide Binders","volume":"156","author":"Shimizu","year":"1996","journal-title":"J. Immunol. Baltim. Md. 1950"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1126\/science.286.5445.1732","article-title":"Arthritis Provoked by Linked T and B Cell Recognition of a Glycolytic Enzyme","volume":"286","author":"Matsumoto","year":"1999","journal-title":"Science"},{"key":"ref_110","first-page":"5788","article-title":"Molecular Basis for Recognition of an Arthritic Peptide and a Foreign Epitope on Distinct MHC Molecules by a Single TCR","volume":"164","author":"Basu","year":"2000","journal-title":"J. Immunol. Baltim. Md. 1950"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1074-7613(00)80045-X","article-title":"From Systemic T Cell Self-Reactivity to Organ-Specific Autoimmune Disease via Immunoglobulins","volume":"10","author":"Korganow","year":"1999","journal-title":"Immunity"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1084\/jem.194.3.321","article-title":"Genetic Influences on the End-Stage Effector Phase of Arthritis","volume":"194","author":"Ji","year":"2001","journal-title":"J. Exp. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/ni772","article-title":"How Antibodies to a Ubiquitous Cytoplasmic Enzyme May Provoke Joint-Specific Autoimmune Disease","volume":"3","author":"Matsumoto","year":"2002","journal-title":"Nat. Immunol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1002\/art.22859","article-title":"Circulating C3 Is Necessary and Sufficient for Induction of Autoantibody-Mediated Arthritis in a Mouse Model","volume":"56","author":"Monach","year":"2007","journal-title":"Arthritis Rheum."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s10875-011-9562-2","article-title":"KRN\/I-Ag7 Mouse Arthritis Is Independent of Complement C3","volume":"31","author":"Tsao","year":"2011","journal-title":"J. Clin. Immunol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/1521-4141(200203)32:3<644::AID-IMMU644>3.0.CO;2-5","article-title":"Transmission of Antibody-Induced Arthritis Is Independent of Complement Component 4 (C4) and the Complement Receptors 1 and 2 (CD21\/35)","volume":"32","author":"Solomon","year":"2002","journal-title":"Eur. J. Immunol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"7926","DOI":"10.1073\/pnas.1820892116","article-title":"Small-Molecule Factor B Inhibitor for the Treatment of Complement-Mediated Diseases","volume":"116","author":"Schubart","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Hornum, L., Hansen, A.J., Tornehave, D., Fjording, M.S., Colmenero, P., W\u00e4tjen, I.F., S\u00f8e Nielsen, N.H., Bliddal, H., and Bartels, E.M. (2017). C5a and C5aR Are Elevated in Joints of Rheumatoid and Psoriatic Arthritis Patients, and C5aR Blockade Attenuates Leukocyte Migration to Synovial Fluid. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0189017"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nrneph.2017.37","article-title":"Complement in ANCA-Associated Vasculitis: Mechanisms and Implications for Management","volume":"13","author":"Chen","year":"2017","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.autrev.2011.08.001","article-title":"Pathogenesis of Takayasu\u2019s Arteritis: A 2011 Update","volume":"11","author":"Arnaud","year":"2011","journal-title":"Autoimmun. Rev."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s12016-014-8453-8","article-title":"Vasculitides and the Complement System: A Comprehensive Review","volume":"49","author":"Chimenti","year":"2015","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2353\/ajpath.2007.060573","article-title":"Alternative Complement Pathway in the Pathogenesis of Disease Mediated by Anti-Neutrophil Cytoplasmic Autoantibodies","volume":"170","author":"Xiao","year":"2007","journal-title":"Am. J. Pathol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1172\/JCI0215918","article-title":"Antineutrophil Cytoplasmic Autoantibodies Specific for Myeloperoxidase Cause Glomerulonephritis and Vasculitis in Mice","volume":"110","author":"Xiao","year":"2002","journal-title":"J. Clin. Investig."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1681\/ASN.2013020143","article-title":"C5a Receptor (CD88) Blockade Protects against MPO-ANCA GN","volume":"25","author":"Xiao","year":"2014","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s10875-008-9268-2","article-title":"Complement Activation Is Involved in Renal Damage in Human Antineutrophil Cytoplasmic Autoantibody Associated Pauci-Immune Vasculitis","volume":"29","author":"Xing","year":"2009","journal-title":"J. Clin. Immunol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/s13075-017-1458-y","article-title":"Platelets Are Activated in ANCA-Associated Vasculitis via Thrombin-PARs Pathway and Can Activate the Alternative Complement Pathway","volume":"19","author":"Miao","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13075-015-0656-8","article-title":"Plasma Complement Factor H Is Associated with Disease Activity of Patients with ANCA-Associated Vasculitis","volume":"17","author":"Chen","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.clim.2016.11.013","article-title":"The Functional Activities of Complement Factor H Are Impaired in Patients with ANCA-Positive Vasculitis","volume":"175","author":"Chen","year":"2017","journal-title":"Clin. Immunol. Orlando Fla."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"R140","DOI":"10.1186\/ar3873","article-title":"C5a and Its Receptors in Human Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis","volume":"14","author":"Yuan","year":"2012","journal-title":"Arthritis Res. Ther."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.2215\/CJN.02790313","article-title":"Alternative Complement Pathway Activation Products in Urine and Kidneys of Patients with ANCA-Associated GN","volume":"8","author":"Gou","year":"2013","journal-title":"Clin. J. Am. Soc. Nephrol. CJASN"},{"key":"ref_131","first-page":"1302","article-title":"Limburg Renal Registry Complement in ANCA-Associated Glomerulonephritis","volume":"32","author":"Hilhorst","year":"2017","journal-title":"Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. Eur. Ren. Assoc."},{"key":"ref_132","first-page":"2218","article-title":"Hypocomplementemia in Systemic Sclerosis--Clinical and Serological Correlations","volume":"34","author":"Hudson","year":"2007","journal-title":"J. Rheumatol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"e4459","DOI":"10.1097\/MD.0000000000004459","article-title":"Complement Activation and Effect of Eculizumab in Scleroderma Renal Crisis","volume":"95","author":"Devresse","year":"2016","journal-title":"Med. (Baltim.)"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJM198602063140601","article-title":"Microvascular Deposition of Complement Membrane Attack Complex in Dermatomyositis","volume":"314","author":"Kissel","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0002-9343(75)90537-9","article-title":"Hereditary Complement (C2) Deficiency with Dermatomyositis","volume":"58","author":"Leddy","year":"1975","journal-title":"Am. J. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1001\/archderm.1995.01690240040007","article-title":"Membrane Attack Complex Deposits in Cutaneous Lesions of Dermatomyositis","volume":"131","author":"Hausmann","year":"1995","journal-title":"Arch. Dermatol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1046\/j.1365-2133.2001.04204.x","article-title":"Hereditary Complement (C9) Deficiency Associated with Dermatomyositis","volume":"144","author":"Ichikawa","year":"2001","journal-title":"Br. J. Dermatol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic-Uremic Syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"6786","DOI":"10.1182\/blood-2011-02-333997","article-title":"Long-Term Treatment with Eculizumab in Paroxysmal Nocturnal Hemoglobinuria: Sustained Efficacy and Improved Survival","volume":"117","author":"Kelly","year":"2011","journal-title":"Blood"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa061648","article-title":"The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria","volume":"355","author":"Hillmen","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/S0140-6736(17)31963-3","article-title":"Recombinant Human C1 Esterase Inhibitor for Prophylaxis of Hereditary Angio-Oedema: A Phase 2, Multicentre, Randomised, Double-Blind, Placebo-Controlled Crossover Trial","volume":"390","author":"Riedl","year":"2017","journal-title":"Lancet Lond. Engl."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and Efficacy of Eculizumab in Anti-Acetylcholine Receptor Antibody-Positive Refractory Generalised Myasthenia Gravis (REGAIN): A Phase 3, Randomised, Double-Blind, Placebo-Controlled, Multicentre Study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"917","DOI":"10.7326\/0003-4819-90-6-917","article-title":"Neisseria Meningitidis and Neisseria Gonorrhoeae Bacteremia Associated with C6, C7, or C8 Deficiency","volume":"90","author":"Petersen","year":"1979","journal-title":"Ann. Intern. Med."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0248-8663(88)80021-3","article-title":"[Hereditary C5 deficiency and recurrent Neisseria meningitidis meningitis]","volume":"9","author":"Ducret","year":"1988","journal-title":"Rev. Med. Interne"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000463071","article-title":"The Complement Profile in Clinical Medicine. Inherited and Acquired Conditions Lowering the Serum Concentrations of Complement Component and Control Proteins","volume":"6","author":"West","year":"1989","journal-title":"Complement Inflamm."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.smim.2016.06.001","article-title":"New Milestones Ahead in Complement-Targeted Therapy","volume":"28","author":"Ricklin","year":"2016","journal-title":"Semin. Immunol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/nbt1344","article-title":"Discovery and Development of the Complement Inhibitor Eculizumab for the Treatment of Paroxysmal Nocturnal Hemoglobinuria","volume":"25","author":"Rother","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1161\/01.CIR.0000087404.53661.F8","article-title":"Effect of Pexelizumab, an Anti-C5 Complement Antibody, as Adjunctive Therapy to Fibrinolysis in Acute Myocardial Infarction: The COMPlement Inhibition in Myocardial Infarction Treated with ThromboLYtics (COMPLY) Trial","volume":"108","author":"Mahaffey","year":"2003","journal-title":"Circulation"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1161\/01.CIR.0000087447.12918.85","article-title":"Pexelizumab, an Anti-C5 Complement Antibody, as Adjunctive Therapy to Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction: The COMplement Inhibition in Myocardial Infarction Treated with Angioplasty (COMMA) Trial","volume":"108","author":"Granger","year":"2003","journal-title":"Circulation"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1182\/blood-2014-02-522128","article-title":"Paroxysmal Nocturnal Hemoglobinuria","volume":"124","author":"Brodsky","year":"2014","journal-title":"Blood"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMoa031688","article-title":"Effect of Eculizumab on Hemolysis and Transfusion Requirements in Patients with Paroxysmal Nocturnal Hemoglobinuria","volume":"350","author":"Hillmen","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood-2007-06-094136","article-title":"Multicenter Phase 3 Study of the Complement Inhibitor Eculizumab for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria","volume":"111","author":"Brodsky","year":"2008","journal-title":"Blood"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/bjh.12347","article-title":"Long-Term Safety and Efficacy of Sustained Eculizumab Treatment in Patients with Paroxysmal Nocturnal Haemoglobinuria","volume":"162","author":"Hillmen","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1182\/blood-2007-06-095646","article-title":"Effect of the Complement Inhibitor Eculizumab on Thromboembolism in Patients with Paroxysmal Nocturnal Hemoglobinuria","volume":"110","author":"Hillmen","year":"2007","journal-title":"Blood"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/ajh.24278","article-title":"Impact of Eculizumab Treatment on Paroxysmal Nocturnal Hemoglobinuria: A Treatment versus No-Treatment Study","volume":"91","author":"Loschi","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1182\/blood-2016-11-709865","article-title":"HUS and Atypical HUS","volume":"129","author":"Jokiranta","year":"2017","journal-title":"Blood"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ki.2014.423","article-title":"Efficacy and Safety of Eculizumab in Atypical Hemolytic Uremic Syndrome from 2-Year Extensions of Phase 2 Studies","volume":"87","author":"Licht","year":"2015","journal-title":"Kidney Int."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","article-title":"Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial","volume":"68","author":"Fakhouri","year":"2016","journal-title":"Am. J. Kidney Dis. Off. J. Natl. Kidney Found."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","article-title":"Eculizumab Is a Safe and Effective Treatment in Pediatric Patients with Atypical Hemolytic Uremic Syndrome","volume":"89","author":"Greenbaum","year":"2016","journal-title":"Kidney Int."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1055\/s-0034-1375299","article-title":"Treatment of C3 Glomerulopathy with Complement Blockers","volume":"40","author":"Vivarelli","year":"2014","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1182\/bloodadvances.2018020644","article-title":"Ravulizumab (ALXN1210) in Patients with Paroxysmal Nocturnal Hemoglobinuria: Results of 2 Phase 1b\/2 Studies","volume":"2","author":"Rottinghaus","year":"2018","journal-title":"Blood Adv."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/blood-2018-09-876136","article-title":"Ravulizumab (ALXN1210) vs. Eculizumab in Adult Patients with PNH Naive to Complement Inhibitors: The 301 Study","volume":"133","author":"Lee","year":"2019","journal-title":"Blood"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.kint.2020.01.035","article-title":"The Long-Acting C5 Inhibitor, Ravulizumab, Is Effective and Safe in Adult Patients with Atypical Hemolytic Uremic Syndrome Na\u00efve to Complement Inhibitor Treatment","volume":"97","author":"Rondeau","year":"2020","journal-title":"Kidney Int."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/j.2326-5205.1989.tb00023.x","article-title":"Successful Plasma Infusion Treatment of a Patient with C2 Deficiency and Systemic Lupus Erythematosus: Clinical Experience over Forty-Five Months","volume":"32","author":"Steinsson","year":"1989","journal-title":"Arthritis Rheum."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"8563","DOI":"10.1073\/pnas.93.16.8563","article-title":"Amelioration of Lupus-like Autoimmune Disease in NZB\/WF1 Mice after Treatment with a Blocking Monoclonal Antibody Specific for Complement Component C5","volume":"93","author":"Wang","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1182\/bloodadvances.2018019596","article-title":"Complement-Mediated Thrombotic Microangiopathy Associated with Lupus Nephritis","volume":"2","author":"Park","year":"2018","journal-title":"Blood Adv."},{"key":"ref_168","first-page":"2286","article-title":"Eculizumab as Rescue Therapy in Severe Resistant Lupus Nephritis","volume":"54","author":"Pickering","year":"2015","journal-title":"Rheumatol. Oxf. Engl."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00467-014-2944-y","article-title":"Dramatic Effects of Eculizumab in a Child with Diffuse Proliferative Lupus Nephritis Resistant to Conventional Therapy","volume":"30","author":"Coppo","year":"2015","journal-title":"Pediatr. Nephrol. Berl. Ger."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s00296-017-3686-5","article-title":"Expanding the Therapeutic Options for Renal Involvement in Lupus: Eculizumab, Available Evidence","volume":"37","author":"Sciascia","year":"2017","journal-title":"Rheumatol. Int."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.semarthrit.2018.11.005","article-title":"Secondary Thrombotic Microangiopathy in Systemic Lupus Erythematosus and Antiphospholipid Syndrome, the Role of Complement and Use of Eculizumab: Case Series and Review of Literature","volume":"49","author":"Kello","year":"2019","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1053\/j.ajkd.2014.07.031","article-title":"Thrombotic Microangiopathy in Systemic Lupus Erythematosus: Efficacy of Eculizumab","volume":"65","author":"Hannan","year":"2015","journal-title":"Am. J. Kidney Dis. Off. J. Natl. Kidney Found."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1111\/j.1600-6143.2011.03696.x","article-title":"Eculizumab in Acute Recurrence of Thrombotic Microangiopathy after Renal Transplantation","volume":"11","author":"Hadaya","year":"2011","journal-title":"Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl. Surg."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1002\/art.34440","article-title":"Brief Report: Induction of Sustained Remission in Recurrent Catastrophic Antiphospholipid Syndrome via Inhibition of Terminal Complement with Eculizumab","volume":"64","author":"Shapira","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1046\/j.1365-2249.2000.01129.x","article-title":"Soluble Complement Receptor One (SCR1) Inhibits the Development and Progression of Rat Collagen-Induced Arthritis","volume":"119","author":"Goodfellow","year":"2000","journal-title":"Clin. Exp. Immunol."},{"key":"ref_176","first-page":"6341","article-title":"Identification of a Selective Nonpeptide Antagonist of the Anaphylatoxin C3a Receptor That Demonstrates Antiinflammatory Activity in Animal Models","volume":"166","author":"Ames","year":"2001","journal-title":"J. Immunol. Baltim. Md. 1950"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1002\/art.10449","article-title":"Antiarthritic Activity of an Orally Active C5a Receptor Antagonist against Antigen-Induced Monarticular Arthritis in the Rat","volume":"46","author":"Woodruff","year":"2002","journal-title":"Arthritis Rheum."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"48921","DOI":"10.1074\/jbc.M302598200","article-title":"Generation of a Recombinant, Membrane-Targeted Form of the Complement Regulator CD59: Activity in Vitro and in Vivo","volume":"278","author":"Fraser","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1002\/art.34430","article-title":"Treatment of Experimental Arthritis by Targeting Synovial Endothelium with a Neutralizing Recombinant Antibody to C5","volume":"64","author":"Macor","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_180","doi-asserted-by":"crossref","unstructured":"Durigutto, P., Macor, P., Ziller, F., De Maso, L., Fischetti, F., Marzari, R., Sblattero, D., and Tedesco, F. (2013). Prevention of Arthritis by Locally Synthesized Recombinant Antibody Neutralizing Complement Component C5. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0058696"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1093\/rheumatology\/kem222","article-title":"Blocking the Receptor for C5a in Patients with Rheumatoid Arthritis Does Not Reduce Synovial Inflammation","volume":"46","author":"Vergunst","year":"2007","journal-title":"Rheumatol. Oxf. Engl."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.clim.2013.02.014","article-title":"Targeting the Complement System in Systemic Lupus Erythematosus and Other Diseases","volume":"148","author":"Toder","year":"2013","journal-title":"Clin. Immunol. Orlando Fla."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"P275","DOI":"10.1186\/1546-0096-12-S1-P275","article-title":"A Difficult Case of Juvenile Dermatomyositis Complicated by Thrombotic Microangiopathy and Purtscher-like Retinopathy","volume":"12","author":"Vanoni","year":"2014","journal-title":"Pediatr. Rheumatol."},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Bekker, P., Dairaghi, D., Seitz, L., Leleti, M., Wang, Y., Ertl, L., Baumgart, T., Shugarts, S., Lohr, L., and Dang, T. (2016). Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0164646"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1681\/ASN.2016111179","article-title":"Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis","volume":"28","author":"Jayne","year":"2017","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/acr2.11185","article-title":"Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis","volume":"2","author":"Merkel","year":"2020","journal-title":"ACR Open Rheumatol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.molimm.2019.07.030","article-title":"Compendium of Current Complement Therapeutics","volume":"114","author":"Zelek","year":"2019","journal-title":"Mol. Immunol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jaci.2010.10.030","article-title":"The IgG Molecule as a Biological Immune Response Modifier: Mechanisms of Action of Intravenous Immune Serum Globulin in Autoimmune and Inflammatory Disorders","volume":"127","author":"Ballow","year":"2011","journal-title":"J. Allergy Clin. Immunol."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/1\/148\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:10:42Z","timestamp":1760159442000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/1\/148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,13]]},"references-count":188,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1]]}},"alternative-id":["cells10010148"],"URL":"https:\/\/doi.org\/10.3390\/cells10010148","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,13]]}}}